Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has announced Professor Ursula Wiedermann will present on the HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
Professor Wiedermann is the co-inventor of the HER-Vaxx cancer vaccine and member of the company’s scientific advisory board.
The abstract presentation is entitled ‘A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach.’
It was authored by Professor Wiedermann and researchers at the Medical University of Vienna in Austria and Imugene.
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.
The company said it has been shown in pre-clinical and Phase 1 studies to stimulate a potent polyclonal antibody response to HER-2/neu, which is a validated cancer target.